demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
potential COVID-19 treatments
adjuvant therapies
anticoagulant
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
clarithromycine Rashad ...
colchicine COL-COVID ...
non-steroidal anti-inflammatory drugs
Indomethacin Ravichandran
Immunostimulants drugs
convalescent plasma treatment Libster
interferon
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
interferon / TFF2 Fu
peginterferon Jagannathan
PNB001 Lattmann
neutralizing antibody
casirivimab/imdevimab (Ronapreve) Somersan-Karakaya ...
Immunosuppressants drugs
anakinra CORIMUNO-ANA-1
lenzilumab LIVE-AIR ...
antiandrogenic
progesterone Ghandehari
antiviral and associated therapy
azithromycin Rashad A ... COALITION I Covid-19 Brazil ...
azvudine Ren
bromhexine Li T
chloroquine and derivatives
hydroxychloroquine Coalition Covid-19 Brazil I ... FACCT Trial
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir Udwadia AVIFAVIR Solaymani-Dodaran NCT04542694 Dabbous HM Ruzhentsova T FACCT Trial Shinkai
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine Coalition Covid-19 Brazil I ...
ivermectin Shahbaznejad Krolewiecki Chaccour Kirti I-TECH ...
ivermectin plus doxycycline NCT04523831 ...
lopinavir/ritonavir ELACOI ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
remdesivir GS-US-540-5773 ... GS-US-540-5774, 10 days GS-US-540-5774, 5 days
sofosbuvir and ledipasvir Nourian A
umifenovir (arbidol) ELACOI ...
miscellaneous
Cannabidiol Crippa ...
sabizabulin VERU-111
Renin-angiotensin-system-acting agents
discontinuation of ACEI/ARB Lopes ...

0 studies excluded by filtering options 0